Publications by authors named "Mark Sherrid"

Claim this Profile
L
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks: Insights From the VALOR-HCM Trial.
Milind Y Desai, Yuichiro Okushi, Kathy Wolski, Jeffrey B Geske, Anjali Tiku Owens, Mark V Sherrid

JACC Cardiovasc Imaging· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left Atrial Appendage Thrombus in Hypertrophic Cardiomyopathy With Atrial Fibrillation-Common and Resistant to Treatment.
Daniele Massera, Mark V Sherrid

J Am Heart Assoc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covert Transthyretin Amyloidosis Mimicking Advanced Obstructive Hypertrophic Cardiomyopathy Despite Multiple Negative Tc-PYP Radionuclide Scans.
Maria Reuter, Woon Wu, Daniele Massera, Lawrence Phillips, Fang Zhou, Mark Sherrid

JACC Case Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy.
Sara Saberi, Christopher M Kramer, Artur Oręziak, Ahmad Masri, Roberto Barriales-Villa, Mark Sherrid

Circulation· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.
Olives Nguyen, Jack Wiedrick, Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Mark Sherrid

medRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.
Ahmad Masri, Mark V Sherrid, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M Kramer

J Card Fail· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Sara Saberi, Theodore P Abraham, Lubna Choudhury, Roberto Barriales-Villa, Perry M Elliott, Mark V Sherrid

JACC Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y Wu, Maria C Reuter, Mark V Sherrid

J Am Heart Assoc· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.
Milind Y Desai, Anjali Owens, Sara Saberi, Andrew Wang, Kathy Wolski, Mark Sherrid

Circ Genom Precis Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
Milind Y Desai, Kathy Wolski, Anjali Owens, Jeffrey B Geske, Sara Saberi, Mark Sherrid

Circulation· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM.
Milind Y Desai, Kathy Wolski, Anjali Owens, Jeffrey B Geske, Sara Saberi, Mark Sherrid

Circulation· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited Concordance of Left Ventricular Ejection Fraction and Chamber Dimensions With Automated Assessments in Hypertrophic Cardiomyopathy: A Substudy From VALOR-HCM.
Gary Parizher, Alice Haouzi, Wael A Jaber, Anjali Owens, Kathy Wolski, Mark Sherrid

J Am Soc Echocardiogr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ahmad Masri, Martin S Maron, Theodore P Abraham, Michael E Nassif, Roberto Barriales-Villa, Mark V Sherrid

JACC Heart Fail· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.
Milind Y Desai, Yuichiro Okushi, Kathy Wolski, Jeffrey B Geske, Anjali Owens, Mark Sherrid

JACC Cardiovasc Imaging· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disopyramide for symptomatic obstructive hypertrophic cardiomyopathy.
Mark V Sherrid, Daniele Massera

Int J Cardiol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical, Surgical, and Interventional Management of Hypertrophic Cardiomyopathy.
Daniele Massera, Mark V Sherrid, Joshua A Scheinerman, Daniel G Swistel, Louai Razzouk

Circ Cardiovasc Interv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Curation of Genes Associated With Hypertrophic Cardiomyopathy: What to Leave In, What to Leave Out.
Mark V Sherrid, Anjali T Owens, Daniele Massera

J Am Coll Cardiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years.
Daniele Massera, Mark V Sherrid, Elizabeth Adlestein, Nadia Bokhari, Isabel C Alvarez

J Am Heart Assoc· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.
Heidi S Lumish, Mark V Sherrid, Paul M L Janssen, Giovanni Ferrari, Kohei Hasegawa

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM.
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, Perry Elliott, Martin S Maron, Mark V Sherrid

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unmasking Obstruction in Hypertrophic Cardiomyopathy With Postprandial Resting and Treadmill Stress Echocardiography.
Daniele Massera, Clarine Long, Yuhe Xia, Les James, Elizabeth Adlestein, Mark V Sherrid

J Am Soc Echocardiogr· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Course and Treatment of Patients With Apical Aneurysms Due to Hypertrophic Cardiomyopathy.
Mark V Sherrid, Daniele Massera, Samuel Bernard, Nidhi Tripathi, Yash Patel

JACC Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.
Milind Y Desai, Yuichiro Okushi, Andrew Gaballa, Qiuqing Wang, Jeffrey B Geske, Mark Sherrid

Circ Cardiovasc Imaging· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.
Milind Y Desai, Anjali Owens, Kathy Wolski, Jeffrey B Geske, Sara Saberi, Mark Sherrid

J Am Coll Cardiol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotype Analysis as a Clinical Tool for Families in Hypertrophic Cardiomyopathy.
Mark V Sherrid, Daniele Massera

JACC Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis